Alphabet's GV Leads Funding in Gene Editing Company Verve Therapeutics

GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

from RSS Feeds : RSS NEWS Feed - NDTV Gadgets360.com http://bit.ly/2DTO11A